钙拮抗剂对大鼠肝硬化模型门脉高压的实验研究  

EXPERIMENTAL STUDY THE EFFECTS OF CA2+ ANTAGONISTS 0N RAT MODEL OF CIRRHOSIS WITH PORTAL HYPERTENSION

作　　者：胡颖[1] 王秀玲[1] 李定国[1] 陆汉明[1] 顾鹤定[1] 施佩蘅 陆玲娣 顾巧德 

机构地区：[1]上海市第二医科大学新华医院

出　　处：《中华消化杂志》1995年第2期89-91,共3页Chinese Journal of Digestion

摘　　要：本文旨在观察细胞膜和细胞内钙拮抗剂单独与联合使用对正常大鼠和肝硬化门脉高压大鼠门脉压力的影响。实验分两部分进行：（一）钙拮抗剂对钙离子诱导大鼠门脉压力升高的影响；（二）钙拮抗剂预防及阻止鼠肝硬化门脉高压症的研究。结果表明，硫氮酮（ＤＩＬ）能有效地预防ＣＣｌ４诱发的鼠肝硬化门脉高压；联合使用尼卡地平（ＮＩＣ）和ＤＩＬ可有效地降低肝硬化门脉高压和抑制钙离子所引起的门脉压升高，与二者单独使用差异有非常显著性统计学。This paper aims at observing the effect of combined use of calcium antagonist(CaA)which acts on the cell membrane(diltiazem) and that acts intracellularly(nicardipine) on theportal venous pressure of normal rats and that of the rat model of cirrhosis with portalhypertension, Two experiments were included in this study.) the effect of CaA onCa2+-induced elevation of portal venous pressure;(2)study of CaA on prevention and arrest ofrat liver cirrhosis with portal hypertension. The results showed that diltiazem (DIL) couldeffectively inhibit an elevation of portal venous pressure in CCl4-induced rat cirrhosis model:combined use of NIC and DIL could effectively reduce cirrhotic portal hypertension andinhibit the Ca2+-induced increase in portal pressure,as compared with the use of DIL alone。

关 键 词：肝硬变 门脉高血压 钙拮抗剂 硫氮卓酮 尼卡地平 

分 类 号：R575.202[医药卫生—消化系统]